{"id":"W4389247829","doi":"10.1182/blood-2023-173692","title":"Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Surrogate endpoint; Adverse effect; Regimen; Gastroenterology; Chemotherapy regimen; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00327612,0.0005462041,0.001533961,0.0003027257,0.0005050729,0.00137371,0.0004449416,0.0006619715,0.001631353],"category_scores_gemma":[0.001609841,0.0002161037,0.001261784,0.0004363204,0.0003025266,0.0007428847,0.0002724228,0.001528989,0.0006740459],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007882513,"about_ca_system_score_gemma":0.0006120442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007204572,"about_ca_topic_score_gemma":0.001737645,"domain_scores_codex":[0.9991254,0.0002453783,0.00009451538,0.0001423034,0.000179312,0.0002131191],"domain_scores_gemma":[0.9982324,0.0003762977,0.0005355204,0.0001834271,0.0002494937,0.0004228606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1471605,0.0115284,0.2436046,0.001482536,0.005301352,0.001316659,0.000843758,0.002248297,0.0853565,0.0002903097,0.01770489,0.4831621],"study_design_scores_gemma":[0.04168548,0.1940052,0.6960222,0.000365028,0.00500667,0.003910253,0.0003098928,0.002562598,0.01868704,0.0003737031,0.03696395,0.0001079674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817097,0.01174865,0.0006284735,0.000477936,0.0000672828,0.0004840663,0.001528479,0.00008893569,0.003266542],"genre_scores_gemma":[0.9922227,0.00200651,0.0004454989,0.000906328,0.00008512706,0.0002257919,0.003314578,0.00002178454,0.0007716398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00327612,"threshold_uncertainty_score":0.017326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0162297430801629,"score_gpt":0.2860685783572566,"score_spread":0.2698388352770937,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}